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Lipoprotein (a) [Lp(a)] is a complex of apolipoprotein
(a) [apo(a)] and low density lipoprotein, which is an
independent major risk factor associated with
atherothrombotic disease 1. Unlike other lipoproteins,
interindividual differences in Lp(a) plasma concentration
is almost entirely due to inheritance, most of them being
attributed to sequence differences linked to the apo(a)
locus.2,3,4 The primary structure of apo(a) encompasses a
protease domain, a kringle V domain and a variable
number of kringle IV repeats, which is homologous to
the same domain in the plasminogen molecule and is
thought to be responsible for the antifibrinolytic activity
of Lp(a). The gene contains a pentanucleotide repeat
(TTTTA)n polymorphism, 1.4 Kb upstream from the
apo(a) gene reading frame. Eight different alleles have
been detected to date, with the number of TTTTA
repeats ranging from 5 to 12.5 This polymorphism, first
described by Wade et al in 1993,6 has been suggested to
be important in the control of apo(a) gene expression.
Alleles containing more repeats were generally associat-
ed with lower plasma Lp(a) concentration. 1,5,7
The aim of this study was to investigate a possible
link between the number of TTTTA repeats and
atherothrombotic serum Lp(a) concentrations [Lp(a) > 30
mg/dL] 7.
We studied 96 unrelated pediatric patients, without
chronic disease or history of thromboembolic events.
These patients - 51 with serum Lp(a) concentrations
above 30 mg/dL (Group 1) and 45 with concentrations
below 30 mg/dL (Group 2) - were age- and gender-
matched; the median age of group 1 was 11.13 years
(range: 2.9 to 18 years, SD: 4.6 years) and of group 2 was
13.1 year (range: 4 to 18.1 years, SD: 3.57 years), respec-
tively; male: female distribution, 1:0.71. The mean (±
SD) value for Lp(a) plasma concentration, performed by
an immunoturbidimetric method, was 84.89 ± 46.4
mg/dL (range: 34 to 165 mg/dL) and 14.83 ± 6.39 mg/dL
(range: 1 to 29 mg/dL), for Groups 1 and 2, respectively.
Genomic DNA was extracted from peripheral blood
leukocytes using standard methods. Genotyping of the
polymorphism in the 5´control region of the apo(a) gene
was performed by fluorescence labeled polymerase
chain reaction with primers described by Mooser et al.5.
The amplified DNA fragments were separated by auto-
mated capillary electrophoresis and subsequently ana-
lyzed with the ABI GeneScan program (Applied
Biosystems) (Figure 1). The number of TTTTA repeats
was confirmed in samples of homozygous patients for
(TTTTA)8 and (TTTTA)9, by automated sequencing. 
The c2 test was used to compare the apo(a) allele fre-
quency in each group. A p-value less than 0.05 was con-
sidered to be statistically significant. 
In this population, the apo(a) allele with (TTTTA)8
was the most common with a frequency of 76.04%.
Alleles with 9, 10, 11, and 7 TTTTA repeats accounted
for 13.02, 8.33, 1.56 and 1.04% respectively (Table I). No
difference was found in the genotype distribution
between the two groups, with Lp(a) < and > 30 mg/dL
(c2=2.527; p>0.05). Homozygosity for the (TTTTA)8
allele was found in 51.1 % of children with Lp(a) levels
below and in 64.7% with Lp(a) levels above the cut-off
point, although this was not statistically significant (χ2=
1.302 ; p>0.05).
To date, no similar study has been carried out in a
pediatric population. Nevertheless, since Lp(a) levels are
almost entirely genetically determined, our data may be
compared to other adult Caucasian data. As such the
allele frequencies found here for the pentanucleotide
repeat polymorphism were similar to those previously
described for other adult Caucasian populations 1. We
did not find statistically significant differences between
the two groups of patients, suggesting that the polymor-
phism might not be directly linked with atherothrom-
botic serum lipoprotein (a) levels. Our sample size, how-
ever, might have some influence on the statistical signif-
icance of these findings. 
The method that we used here is easy, reliable and
inexpensive and allows for successful genotyping of the
Figure 1. 
Table 1. 
pentanucleotide repeat polymorphism in the apo(a)
gene.
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